17q21.31 microduplication syndrome

17q21.31 microduplication syndrome (also known as 17q21.31 duplication syndrome) is a rare chromosomal disorder caused by a small duplication of genetic material on the long arm of chromosome 17, in the region q21.31. This region overlaps with the region deleted in the well-characterized Koolen-de Vries syndrome (17q21.31 microdeletion syndrome), and the duplication involves genes including MAPT (microtubule-associated protein tau) and KANSL1. The condition is identified through chromosomal microarray analysis and affects multiple body systems, primarily the neurological and musculoskeletal systems. Clinical features of 17q21.31 microduplication syndrome are variable and can include intellectual disability or learning difficulties, speech and language delay, behavioral abnormalities, and psychomotor developmental delay. Some individuals may present with dysmorphic facial features, hypotonia (reduced muscle tone), and seizures. Growth abnormalities and congenital anomalies affecting the heart or other organs have also been reported in some cases. The phenotypic spectrum is broad, and some carriers of the duplication may be mildly affected or even asymptomatic, which complicates genotype-phenotype correlations. There is currently no specific cure or targeted therapy for 17q21.31 microduplication syndrome. Management is supportive and symptom-based, typically involving early intervention programs, speech therapy, occupational therapy, physical therapy, and special educational support. Seizures, if present, are managed with standard antiepileptic medications. Regular developmental assessments and multidisciplinary follow-up are recommended to optimize outcomes. Genetic counseling is important for affected families, as the duplication may be inherited from a mildly affected or apparently unaffected parent.

Common questions about 17q21.31 microduplication syndrome